Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from PolyPeptide Group AG ( (CH:PPGN) ).
PolyPeptide Group AG has expanded its revolving credit facility by EUR 40 million to EUR 151 million, with an extension until March 2028, supported by UBS, Danske Bank, and Zürcher Kantonalbank. This financial boost, alongside increased support from main shareholder Draupnir Holding B.V., enhances PolyPeptide’s financial flexibility to pursue growth, aiming to double its 2023 revenues by 2028, particularly in the metabolic diseases and GLP-1 sectors.
The most recent analyst rating on (CH:PPGN) stock is a Hold with a CHF33.50 price target. To see the full list of analyst forecasts on PolyPeptide Group AG stock, see the CH:PPGN Stock Forecast page.
More about PolyPeptide Group AG
PolyPeptide Group AG is a specialized contract developer and manufacturer (CDMO) focusing on peptide- and oligonucleotide-based active pharmaceutical ingredients. The company serves the pharmaceutical and biotech sectors, contributing to the health of millions globally. It operates six GMP-certified production facilities worldwide and is listed on the SIX Swiss Exchange.
Average Trading Volume: 65,555
Current Market Cap: CHF642.8M
See more insights into PPGN stock on TipRanks’ Stock Analysis page.